What is he best known for?
The fields of study he is best known for:
His primary scientific interests are in Molecular biology, Antibody, Biochemistry, Antigen and Peptide sequence.
His Molecular biology study combines topics from a wide range of disciplines, such as Monoclonal antibody, CD3 and Recombinant DNA, Fusion protein.
Melvyn Little has researched Recombinant DNA in several fields, including Phage display, Immunology, Genetically engineered, Peptide library and Computational biology.
Melvyn Little usually deals with Antibody and limits it to topics linked to Peptide and Combinatorial chemistry, Histidine and Immunoglobulin Fragments.
His research investigates the connection with Biochemistry and areas like Tubulin which intersect with concerns in Enzyme and Protein primary structure.
His study looks at the intersection of Antigen and topics like Phagemid with Plasmid, Immunoglobulin heavy chain, Immunoglobulin G and Immunoglobulin light chain.
His most cited work include:
- A surface expression vector for antibody screening. (279 citations)
- Targeting recombinant antibodies to the surface of Escherichia coli: fusion to a peptidoglycan associated lipoprotein. (256 citations)
- Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. (240 citations)
What are the main themes of his work throughout his whole career to date?
Melvyn Little mainly investigates Molecular biology, Antibody, Biochemistry, Antigen and Recombinant DNA.
Melvyn Little interconnects Single-Chain Antibodies, Monoclonal antibody, Immunoglobulin light chain, Fusion protein and CD3 in the investigation of issues within Molecular biology.
His work on Phage display is typically connected to Linker as part of general Antibody study, connecting several disciplines of science.
Melvyn Little has researched Biochemistry in several fields, including Tubulin and Microtubule.
Melvyn Little studied Antigen and Immunotherapy that intersect with Cancer research.
Melvyn Little combines subjects such as Amino acid and Physarum with his study of Peptide sequence.
He most often published in these fields:
- Molecular biology (50.27%)
- Antibody (45.99%)
- Biochemistry (25.67%)
What were the highlights of his more recent work (between 2009-2017)?
- Cancer research (8.56%)
- Molecular biology (50.27%)
- Antibody (45.99%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Cancer research, Molecular biology, Antibody, CD3 and Cytotoxicity.
His study on Molecular biology also encompasses disciplines like
- Cancer cell which connect with Angiogenesis,
- Amyloid beta which connect with Transport protein.
Antibody is a subfield of Immunology that he investigates.
Melvyn Little has included themes like Antigen binding, B cell, Polypeptide chain, Molecule and CD19 in his CD3 study.
His work focuses on many connections between Cytotoxicity and other disciplines, such as Cytotoxic T cell, that overlap with his field of interest in Antigen.
His work carried out in the field of Antigen brings together such families of science as T cell and Pharmacology.
Between 2009 and 2017, his most popular works were:
- A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells (94 citations)
- A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells (86 citations)
- 68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours (42 citations)
In his most recent research, the most cited papers focused on:
Melvyn Little spends much of his time researching Molecular biology, Antibody, Cytotoxic T cell, Antigen and Cancer cell.
His Molecular biology research is multidisciplinary, incorporating elements of Recombinant antibodies, Pathogenesis, Receptor, Endocytosis and Cell biology.
His Antibody research includes themes of Recombinant DNA and Cytotoxicity.
The concepts of his Cytotoxicity study are interwoven with issues in Interleukin 21, Allotype, CD30, CD3 and Immunotherapy.
The various areas that Melvyn Little examines in his Cytotoxic T cell study include B cell and CD19.
His Cancer cell study deals with Cancer research intersecting with Cell and Esophageal cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
